Free Trial

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity logo
$102.96 +0.29 (+0.28%)
(As of 11/20/2024 ET)

HealthEquity - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
12

Based on 13 Wall Street analysts who have issued ratings for HealthEquity in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for HQY.

Consensus Price Target

$107.23
4.15% Upside
According to the 13 analysts' twelve-month price targets for HealthEquity, the average price target is $107.23. The highest price target for HQY is $130.00, while the lowest price target for HQY is $92.00. The average price target represents a forecasted upside of 4.15% from the current price of $102.96.
Get the Latest News and Ratings for HQY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HealthEquity and its competitors.

Sign Up

HQY Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$107.23$103.83$101.67$84.14
Forecasted Upside4.15% Upside18.52% Upside32.69% Upside26.02% Upside
Consensus Rating
Moderate Buy
Buy
Buy
Buy

HQY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HQY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HealthEquity Stock vs. The Competition

TypeHealthEquityMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside4.15% Upside26,931.82% Upside9.81% Upside
News Sentiment Rating
Positive News

See Recent HQY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2024The Goldman Sachs Group
2 of 5 stars
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$108.00+12.85%
11/14/2024BTIG Research
2 of 5 stars
 Boost TargetBuy ➝ Buy$110.00 ➝ $130.00+34.24%
11/13/2024Bank of America
4 of 5 stars
 Boost TargetBuy ➝ Buy$100.00 ➝ $120.00+24.21%
9/20/2024Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00+31.60%
9/4/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$102.00 ➝ $103.00+25.78%
9/4/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$105.00 ➝ $105.00+28.28%
9/4/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$92.00 ➝ $92.00+18.19%
6/20/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$107.00 ➝ $110.00+29.81%
6/7/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $105.00+23.47%
6/5/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$95.00 ➝ $100.00+19.90%
6/4/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$98.00 ➝ $104.00+28.05%
4/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$86.00 ➝ $108.00+31.39%
2/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$84.00 ➝ $104.00+26.26%
12/7/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$89.00 ➝ $94.00+43.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:09 AM ET.


HQY Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for HealthEquity is $107.23, with a high forecast of $130.00 and a low forecast of $92.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HealthEquity in the last year. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HQY shares.

According to analysts, HealthEquity's stock has a predicted upside of 4.15% based on their 12-month stock forecasts.

HealthEquity has been rated by research analysts at Bank of America, Barrington Research, BTIG Research, Deutsche Bank Aktiengesellschaft, JMP Securities, Royal Bank of Canada, and The Goldman Sachs Group in the past 90 days.

Analysts like HealthEquity more than other "medical" companies. The consensus rating score for HealthEquity is 2.92 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HQY compares to other companies.


This page (NASDAQ:HQY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners